Somatostatin Analogs (e.g., Octreotide, Lanreotide)

Type: drug

Status: FDA Approved

Developer: Novartis (Octreotide), Ipsen (Lanreotide)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026